BRAF and low grade glioma: Accordingly, while Horbinski et al. (2012) [13] showed that in their cohort of pediatric low-grade gliomas, BRAF V600E mutationended to a worse progression-free survival when compared to wild-type tumors, Mistry et al. (2015) [16] showed that this mutation was associated with a prolonged latency to malignant transformation and, consequently, with a better overall survival when compared to wild-type pediatric low-grade gliomas.